I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

APVRS 2024

-
Coming soon
03:12 AM
Duration 6mins Rapid Fire 2 - Intraocular Inflammation, Uveitis & Scleritis
Intravitreal Interleukin-6 Inhibition With Vamikibart in Uveitic Macular Edema: Final Results From the Phase 1 DOVETAIL Study
Agrawal R, Steeples L, Elze M, Macgregor L, Stoilov I, Silverman D, Mesquida M, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:24 AM
Duration 6mins Rapid Fire 2 - Intraocular Inflammation, Uveitis & Scleritis
IL-6 Inhibition with Vamikibart in Patients with Uveitic Macular Edema: Study Design of the Phase 3 MEERKAT and SANDCAT trials
Hwang Y, Steeples L, Elze M, Macgregor L, Silverman D, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:30 AM
Duration 5mins Rapid Fire 3 - Retina (Medical) (1)
Patient Preference for the Port Delivery System With Ranibizumab (PDS) vs Intravitreal Injections: 1-Year Results From the Phase 3 Pagoda Trial in Patients With Diabetic Macular Edema (DME)
Koh A, Chang M, Marcus D, Baldonado K, Daly A, Tian K

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:35 AM
Duration 5mins Rapid Fire 3 - Retina (Medical) (1)
Efficacy, Durability and Safety of Faricimab▼ in DME: 2-Year Results from China Subpopulation of Phase 3 RHINE Trial
Sun X, Chen Q, Shi Y

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:45 AM
Duration 5mins Rapid Fire 3 - Retina (Medical) (1)
Port Delivery System With Ranibizumab for Continuous Treatment in Diabetic Retinopathy: First Readout of 2-Year Data From the Phase 3 Pavilion Trial
Lai T, Chang M, Awh C, Khanani A, Tian K, Latkany P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:10 AM
Duration 5mins Rapid Fire 3 - Retina (Medical) (1)
Faricimab▼ in Diabetic Macular Edema: Results from the RHONE-X Long-Term Extension Trial
Chang A, Sim D, Khanani A, Kotak A, Tang Y, Kotecha A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:05 AM
Duration 5mins Rapid Fire 5 - Retina (Medical) (2)
Response of Large or Serous Pigment Epithelial Detachment to Faricimab▼ versus Aflibercept in Patients with Neovascular Age-related Macular Degeneration: A Subgroup Analysis from TENAYA and LUCERNE
Hsieh Y, Harrell E, Margaron P, Patel S, Yang M, Lai T

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:15 AM
Duration 5mins Rapid Fire 5 - Retina (Medical) (2)
Real-World Effectiveness of Faricimab▼ in Patients with Diabetic Macular Edema: 12-Month Outcomes from FARETINA-DME and FARWIDE-DME Studies
Szeto S, Singh R, Borkar D, Tabano D, Peto T, Dayal P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:35 AM
Duration 5mins Rapid Fire 5 - Retina (Medical) (2)
Faricimab▼ for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial
Cheung G, Iida T, Bai R, Margaron P, Nguyen Duc A, Lai T

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:40 AM
Duration 5mins Rapid Fire 5 - Retina (Medical) (2)
Global Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema From a Multi-Country Prospective Non-Interventional Study: The VOYAGER Study
Koh A, Bailey C, Chi G, Shi B, Uschner D, Guymer R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:10 AM
Duration 5mins Rapid Fire 5 - Retina (Medical) (2)
Real-World Effectiveness of Faricimab▼ in Patients with Neovascular Age-Related Macular Degeneration: 12-Month Outcomes from the FARETINA-nAMD and FARWIDE-nAMD Studies
Lin T, Singh R, Borkar D, Tabano D, Talks J, Dayal P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar